fosbretabulin   Click here for help

GtoPdb Ligand ID: 8857

Synonyms: CA4DP | combretastatin A4 phosphate | fosbretabulin disodium | fosbretabulin tromethamine | Zybrestat (fosbretabulin disodium)
Compound class: Synthetic organic
Comment: Fosbretabulin is being investigated for anti-tumour potential. It interferes with vascularisation by preventing tubulin-polymerisation and disrupting cell junctions [2]. This action destroys tumour vasculature and leads to cancer cell death and necrosis. Mechanistically, fosbretabulin is dephosphorylated to the active tubulin polymerisation inhibitor combretastatin A4 [3]. The compound was originally isolated from the African bush willow (Combretum caffrum) [1,5].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 113.49
Molecular weight 396.1
XLogP 2.21
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(C=Cc2ccc(c(c2)OP(=O)(O)O)OC)cc(c1OC)OC
Isomeric SMILES COc1cc(/C=C\c2ccc(c(c2)OP(=O)(O)O)OC)cc(c1OC)OC
InChI InChI=1S/C18H21O8P/c1-22-14-8-7-12(9-15(14)26-27(19,20)21)5-6-13-10-16(23-2)18(25-4)17(11-13)24-3/h5-11H,1-4H3,(H2,19,20,21)/b6-5-
InChI Key WDOGQTQEKVLZIJ-WAYWQWQTSA-N
No information available.
Summary of Clinical Use Click here for help
Various formulations of fosbretabulin have been advanced to clinical evaluations to determine safety and efficacy against solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01305213 Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Phase 2 Interventional National Cancer Institute (NCI) In this study fosbretabulin was investigated for anti-tumour efficacy in combination with the anti-VEGFA agent ; fosbretabulin to damage existing tumour vasculature and bevacizumab to disrupt revascularisation. 4
NCT00653939 A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer Phase 2 Interventional Mateon Therapeutics